Provided by Tiger Trade Technology Pte. Ltd.

Ventyx Biosciences, Inc.

14.00
0.0000
Volume:- -
Turnover:76.26M
Market Cap:1.00B
PE:-9.34
High:14.00
Open:14.00
Low:14.00
Close:14.00
52wk High:25.00
52wk Low:0.7830
Shares:71.75M
Float Shares:53.56M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4991
EPS(LYR):-1.9732
ROE:-45.35%
ROA:-28.47%
PB:5.25
PE(LYR):-7.10

Loading ...

Company Profile

Company Name:
Ventyx Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.